2 results
Approved WMORecruiting
The primary objective of the study is to determine the efficacy of AP26113, as evidenced by objective response rate, in patients with ALK positive locally advanced or metastatic NSCLC whose disease has progressed on therapy with crizotinib.
Approved WMORecruiting
The primary objective is to determine whether there is a difference in the capability of the patients to successfully follow the instructions of both the Levodopa Cyclops* and the INBRIJA® inhaler during an off episode, based on the instruction…